117782-76-0

Basic information

• Product Name: Pyrazolo[1,5-a]pyridin-3-ylmethanol
• Synonyms: Pyrazolo[1,5-a]pyridin-3-ylmethanol;(H-pyrazolo[1,5-a]pyridin-3-yl)Methanol
• CAS NO: 117782-76-0
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.16
• Mol File: 117782-76-0.mol

Chemical Properties

• Melting Point: 44-46 °C
• Appearance: /
• Density: 1.267g/cm³
• Refractive Index: 1.641
• PKA: 14.08±0.10(Predicted)
• CAS DataBase Reference: Pyrazolo[1,5-a]pyridin-3-ylmethanol(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazolo[1,5-a]pyridin-3-ylmethanol(117782-76-0)
• EPA Substance Registry System: Pyrazolo[1,5-a]pyridin-3-ylmethanol(117782-76-0)

Safety Data

• Hazardous Substances Data: 117782-76-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyrazolo[1,5-a]pyridin-3-ylmethanol is used as a key building block for the synthesis of various pharmaceutical compounds. Its unique ring structure and reactivity allow for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, Pyrazolo[1,5-a]pyridin-3-ylmethanol serves as an essential intermediate in the creation of biologically active molecules. Its incorporation into agrochemical compounds can lead to the development of novel pesticides or other agricultural products with enhanced efficacy and selectivity.
Used in Medicinal Chemistry Research:
Pyrazolo[1,5-a]pyridin-3-ylmethanol is utilized as a valuable intermediate in medicinal chemistry research. Its unique structure and reactivity make it an ideal candidate for exploring new chemical entities with potential therapeutic properties, contributing to the advancement of drug discovery and development.

InChI:InChI=1/C8H8N2O/c11-6-7-5-9-10-4-2-1-3-8(7)10/h1-5,11H,6H2

Upstream product

• 16205-44-0 Pyrazolo<1,5-a>pyridin-3-carbonsaeureethylester 
• 127717-33-3 bis<(pyrazolo<1,5-a>pyrid-3-yl)methyl> ether 
• 63237-84-3 methyl pyrazolo<1,5-a>pyridine-3-carboxylate 

Downstream Products

• 73957-66-1 3-pyrazolo<1,5-a>pyridineacarboxaldehyde 
• 307308-03-8 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carbaldehyde 
• 117782-75-9 (R)-(+)-2-Amino-3-(pyrazolo<1,5-a>pyridin-3-yl)propionsaeure 
• 117782-75-9 (S)-(-)-2-Amino-3-(pyrazolo<1,5-a>pyridin-3-yl)propionsaeure 
• 117782-75-9 2-Amino-3-(pyrazolo<1,5-a>pyridin-3-yl)propionsaeure 
• 117782-82-8 2-(Diphenylmethylenamino)-3(pyrazolo<1,5-a>pyridin-3-yl)propionsaeureethylester 
• 118055-01-9 pyrazolo[1,5-a]pyridin-3-yl-acetonitrile 
• 118054-99-2 3-Pyrazolo<1,5-a>pyridylmethylamin 

Relevant articles and documents

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.

Acid-Catalyzed Reactions of 3-(Hydroxymethyl)- and 3-(1-Hydroxyethyl)pyrazolopyridines

Treatment of 3-(hydroxymethyl)pyrazolopyridines with trifluoroacetic acid in refluxing dichloromethane led to the formation of bis(pyrazolopyrid-3-yl)methanes or bis pyrid-3-yl)>methyl ethers depending upon the concentration of trifluoroacetic acid.In contrast, similar treatment of 3-(1-hydroxyethyl)pyrazolopyridines gave a mixture of 3-vinylpyrazolopyridines and 1,3-bis(pyrazolopyrid-3-yl)-1-butenes.